BT Investment Management Ltd Boosts Position in PAREXEL International Co. (PRXL)
BT Investment Management Ltd lifted its position in shares of PAREXEL International Co. (NASDAQ:PRXL) by 152.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,110 shares of the medical research company’s stock after acquiring an additional 5,500 shares during the period. BT Investment Management Ltd’s holdings in PAREXEL International were worth $802,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the stock. World Asset Management Inc raised its position in shares of PAREXEL International by 0.3% during the 2nd quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 9 shares in the last quarter. 1st Global Advisors Inc. raised its position in shares of PAREXEL International by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,391 shares of the medical research company’s stock valued at $469,000 after acquiring an additional 21 shares in the last quarter. Amalgamated Bank raised its position in shares of PAREXEL International by 0.6% during the 2nd quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock valued at $631,000 after acquiring an additional 42 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in shares of PAREXEL International by 4.5% during the 1st quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after acquiring an additional 73 shares in the last quarter. Finally, Texas Permanent School Fund raised its position in shares of PAREXEL International by 0.5% during the 2nd quarter. Texas Permanent School Fund now owns 37,062 shares of the medical research company’s stock valued at $3,221,000 after acquiring an additional 169 shares in the last quarter. 87.45% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/bt-investment-management-ltd-boosts-position-in-parexel-international-co-prxl/1692933.html.
PAREXEL International Co. has a 52 week low of $51.16 and a 52 week high of $88.10. The company has a current ratio of 1.45, a quick ratio of 1.45 and a debt-to-equity ratio of 1.01.
PAREXEL International (NASDAQ:PRXL) last announced its quarterly earnings data on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.08. The firm had revenue of $557.20 million during the quarter, compared to the consensus estimate of $537.59 million. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. During the same period in the prior year, the business earned $0.94 EPS.
Several equities research analysts recently issued reports on PRXL shares. BidaskClub lowered PAREXEL International from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Zacks Investment Research raised PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research report on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. PAREXEL International currently has an average rating of “Hold” and a consensus price target of $76.81.
PAREXEL International Company Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.